Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or

Trial Details

NCT ID

NCT06445062

Phase

PHASE1 / PHASE2

Sponsor

Revolution Medicines, Inc.

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

RMC-6236
mFOLFOX6 regimen
bevacizumab
mFOLFIRINOX regimen
cetuximab
gemcitabine

Locations (sample)

Chandler, Arizona, United States|33.30616,-111.84125
Phoenix, Arizona, United States|33.44838,-112.07404
Scottsdale, Arizona, United States|33.50921,-111.89903
La Jolla, California, United States|32.84727,-117.2742
Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

All Patients (unless otherwise noted):
≥ 18 years of age
ECOG PS is 0 to 1
Adequate organ function as outlined by the study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →